A Double-blind, Placebo-controled, Crossover Study To Evaluate the Efficacy, Safety and Tolerability of Inhaled ASM8-003 in Subjects With Mild Allergic Asthma.
Sponsor study identifier
interventional
15
1 country
3
Study Start
December 2005
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
Not reported
Date not reportedStudy Completion
April 2006
Actual (reported)To determine the safety and efficacy of multiple doses of ASM8 antisense oligonucleotides in asthmatics.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
April 2006
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
December 2005
Date type not reportedThis date has not been verified as actual or estimated.
December 12, 2005
Actual (reported)December 13, 2005
Actual (reported)April 2006
Actual (reported)Comparison of the allergen-induced late asthmatic response (LAR) between ASM8 and placebo
Evaluation of the safety and tolerability of ASM8.
Comparison of the allergen-induced early asthmatic response (EAR) between ASM8 and placebo.
Comparison of the allergen-induced airway hyperresponsiveness between ASM8 and placebo.
Comparison of the allergen-induced changes in sputum eosinophils at 7 and 24 hours post allergen, between the ASM8 and placebo.
Determination of the plasma and sputum pharmacokinetic profile of single- and repeated-doses of ASM8 in patients with mild asthma.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
McMaster University
Hamilton, Ontario, L8N 3Z5, Canada
Hopital Laval
Ste-Foy, Quebec, G1V 4G5, Canada
Saskatoon Hospital
Saskatoon, Saskatchewan, S7N 0W8, Canada
Gauvreau GM, Boulet LP, Cockcroft DW, Baatjes A, Cote J, Deschesnes F, Davis B, Strinich T, Howie K, Duong M, Watson RM, Renzi PM, O'Byrne PM. Antisense therapy against CCR3 and the common beta chain attenuates allergen-induced eosinophilic responses. Am J Respir Crit Care Med. 2008 May 1;177(9):952-8. doi: 10.1164/rccm.200708-1251OC. Epub 2008 Jan 31.
Paul O'Byrne, MD
McMaster University
First Submitted
December 12, 2005
First Posted
December 13, 2005
Study Start
December 2005
Date type not reportedThis date has not been verified as actual or estimated.
Study Completion
April 2006
Actual (reported)Contact the study team to confirm eligibility.
Last Updated
December 3, 2012
Record last verified: 2012-11
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: